Based on the AURA trials, osimertinib is currently a standard of care for EGFR-mutant NSCLC patients with acquired resistance to first- or second- generation EGFR-TKIs owing to the T790M mutation (18–21). Here, EGFR is linked to non-small cell lung carcinoma.